Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

Eta polycaprolactone (ε-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model

Authors: Benjamin Benzon, Sandra Marijan, Matij Pervan, Vedrana Čikeš Čulić

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cells in every epithelium can be roughly divided in three compartments: stem cell (SC) compartment, transient amplifying cell (TA) compartment and terminally differentiated (TD) compartment. Maturation of stem cells is characterized by epithelial stromal interaction and sequential maturational movement of stem cell’s progeny through those compartments. In this work we hypothesize that providing an artificial stroma, which murine breast cancer metastatic cells can infiltrate, will induce their differentiation.

Methods

BALB/c female mice were injected with 106 isogenic 4T1 breast cancer cells labeled with GFP. After 20 days primary tumors were removed, and artificial ε-PCL implants were implanted on the contralateral side. After 10 more days mice were sacrificed and implants along with lung tissue were harvested. Mice were divided in four groups: tumor removal with sham implantation surgery (n = 5), tumor removal with ε-PCL implant (n = 5), tumor removal with VEGF enriched ε-PCL implant (n = 7) and mice without tumor with VEGF enriched ε-PCL implant (n = 3). Differentiational status of GFP + cells was assessed by Ki67 and activated caspase 3 expression, thus dividing the population in SC like cells (Ki67+/dim aCasp3), TA like cells (Ki67+/dim aCasp3+/dim) and TD like cells (Ki67 aCasp3+/dim) on flow cytometry.

Results

Lung metastatic load was reduced by 33% in mice with simple ε-PCL implant when compared to tumor bearing group with no implant. Mice with VEGF enriched implants had 108% increase in lung metastatic load in comparison to tumor bearing mice with no implants. Likewise, amount of GFP + cells was higher in simple ε-PCL implant in comparison to VEGF enriched implants. Differentiation-wise, process of metastasizing to lungs reduces the average fraction of SC like cells when compared to primary tumor. This effect is made more uniform by both kinds of ε-PCL implants. The opposite process is mirrored in TA like cells compartment when it comes to averages. Effects of both types of implants on TD like cells were negligible. Furthermore, if gene expression signatures that mimic tissue compartments are analyzed in human breast cancer metastases, it turns out that TA signature is associated with increased survival probability.

Conclusion

ε-PCL implants without VEGF can reduce metastatic loads in lungs, after primary tumor removal. Both types of implants cause lung metastasis differentiation by shifting cancer cells from SC to TA compartment, leaving the TD compartment unaffected.
Appendix
Available only for authorised users
Literature
2.
go back to reference Messier B, Leblond CP. Cell proliferation and migration as revealed by radioautography after injection of thymidine-H3 into male rats and mice. Am J Anat. 1960;106(3):247–85.PubMedCrossRef Messier B, Leblond CP. Cell proliferation and migration as revealed by radioautography after injection of thymidine-H3 into male rats and mice. Am J Anat. 1960;106(3):247–85.PubMedCrossRef
3.
go back to reference Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development. 1990;110(4):1001–20.PubMedCrossRef Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development. 1990;110(4):1001–20.PubMedCrossRef
6.
go back to reference Fernando P, Megeney LA. Is caspase-dependent apoptosis only cell differentiation taken to the extreme? Faseb J. 2007;21(1):8–17.PubMedCrossRef Fernando P, Megeney LA. Is caspase-dependent apoptosis only cell differentiation taken to the extreme? Faseb J. 2007;21(1):8–17.PubMedCrossRef
8.
go back to reference Potter JD. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer. 2007;7(6):464–74.PubMedCrossRef Potter JD. Morphogens, morphostats, microarchitecture and malignancy. Nat Rev Cancer. 2007;7(6):464–74.PubMedCrossRef
9.
go back to reference Davies JA. Mechanisms of morphogenesis. 2nd ed. New York: Elsevier Academic Press; 2013. p. 414. Davies JA. Mechanisms of morphogenesis. 2nd ed. New York: Elsevier Academic Press; 2013. p. 414.
11.
go back to reference Baker SG. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2015;107(2):dju405.PubMedCrossRef Baker SG. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2015;107(2):dju405.PubMedCrossRef
12.
go back to reference Billingham RE, Orr JW, Woodhouse DL. Transplantation of skin components during chemical carcinogenesis with 20-methylcholanthrene. Br J Cancer. 1951;5(4):417–32.PubMedPubMedCentralCrossRef Billingham RE, Orr JW, Woodhouse DL. Transplantation of skin components during chemical carcinogenesis with 20-methylcholanthrene. Br J Cancer. 1951;5(4):417–32.PubMedPubMedCentralCrossRef
14.
go back to reference Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004;117(8):1495–502.PubMedCrossRef Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004;117(8):1495–502.PubMedCrossRef
16.
go back to reference Bullough WS. The structure of tumours. In: The Dynamic Body Tissues. 1st ed. Lancaster: MTP Press Limited; 1983. p. 136–8. Bullough WS. The structure of tumours. In: The Dynamic Body Tissues. 1st ed. Lancaster: MTP Press Limited; 1983. p. 136–8.
18.
go back to reference Damjanov I. History and General Aspects of Tumor Grading. In: Damjanov I, Fang F, editors. Cancer Grading Manual. 2nd ed. Heidelberg: Springer, Berlin Heidelberg; 2013. p. 1–7.CrossRef Damjanov I. History and General Aspects of Tumor Grading. In: Damjanov I, Fang F, editors. Cancer Grading Manual. 2nd ed. Heidelberg: Springer, Berlin Heidelberg; 2013. p. 1–7.CrossRef
19.
go back to reference Molina-Peña R, Álvarez MM. A simple mathematical model based on the cancer stem cell hypothesis suggests kinetic commonalities in solid tumor growth. PLoS One. 2012;7(2):e26233.PubMedPubMedCentralCrossRef Molina-Peña R, Álvarez MM. A simple mathematical model based on the cancer stem cell hypothesis suggests kinetic commonalities in solid tumor growth. PLoS One. 2012;7(2):e26233.PubMedPubMedCentralCrossRef
20.
go back to reference Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60(9):2541–6.PubMed Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60(9):2541–6.PubMed
21.
go back to reference Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: An early event in metastatic inefficiency. Cancer Res. 2001;61(1):333–8.PubMed Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: An early event in metastatic inefficiency. Cancer Res. 2001;61(1):333–8.PubMed
23.
go back to reference Overton WR. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry. 1988;9(6):619–26.PubMedCrossRef Overton WR. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry. 1988;9(6):619–26.PubMedCrossRef
24.
go back to reference Shapiro HM. Data analysis. In: Practical flow cytometry. 4th ed. Hoboken, NJ: John Wiley & Sons Inc; 2003. p. 245.CrossRef Shapiro HM. Data analysis. In: Practical flow cytometry. 4th ed. Hoboken, NJ: John Wiley & Sons Inc; 2003. p. 245.CrossRef
25.
go back to reference Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207 Available from: /pmc/articles/PMC99122/. [Cited 2022 Aug 13].PubMedPubMedCentralCrossRef Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207 Available from: /pmc/articles/PMC99122/. [Cited 2022 Aug 13].PubMedPubMedCentralCrossRef
28.
go back to reference Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25 Available from: /pmc/articles/PMC3037419/. [Cited 2022 Aug 13].PubMedPubMedCentralCrossRef Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25 Available from: /pmc/articles/PMC3037419/. [Cited 2022 Aug 13].PubMedPubMedCentralCrossRef
31.
go back to reference Anderson DR. Quantifying the Evidence About Science Hypotheses. In: Model Based Inference in the Life Sciences: A Primer on Evidence. 1st ed. New York: Springer Science+Business Media, LLC; 2008. p. 83–103.CrossRef Anderson DR. Quantifying the Evidence About Science Hypotheses. In: Model Based Inference in the Life Sciences: A Primer on Evidence. 1st ed. New York: Springer Science+Business Media, LLC; 2008. p. 83–103.CrossRef
36.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555 Available from: /pmc/articles/PMC2423808/. [Cited 2022 Aug 21].PubMedPubMedCentralCrossRef Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555 Available from: /pmc/articles/PMC2423808/. [Cited 2022 Aug 21].PubMedPubMedCentralCrossRef
37.
go back to reference Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cells. J Cell Sci. 2005;118(16):3585–94.PubMedCrossRef Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cells. J Cell Sci. 2005;118(16):3585–94.PubMedCrossRef
38.
39.
go back to reference Rudolph MC, McManaman JL, Hunter L, Phang T, Neville MC. Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia. 2003;8(3):287–307. Available from: https://pubmed.ncbi.nlm.nih.gov/14973374/. [Cited 2022 Aug 21]PubMedCrossRef Rudolph MC, McManaman JL, Hunter L, Phang T, Neville MC. Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia. 2003;8(3):287–307. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​14973374/​. [Cited 2022 Aug 21]PubMedCrossRef
42.
go back to reference Scher W, Friend C. Breakage of DNA and Alterations in Folded Genomes by Inducers of Differentiation in Friend Erythroleukemic Cells. Cancer Res. 1978;38(3):841–9.PubMed Scher W, Friend C. Breakage of DNA and Alterations in Folded Genomes by Inducers of Differentiation in Friend Erythroleukemic Cells. Cancer Res. 1978;38(3):841–9.PubMed
43.
go back to reference Carlile GW, Smith DH, Wiedmann M. Caspase-3 has a nonapoptotic function in erythroid maturation. Blood. 2004;103(11):4310–6.PubMedCrossRef Carlile GW, Smith DH, Wiedmann M. Caspase-3 has a nonapoptotic function in erythroid maturation. Blood. 2004;103(11):4310–6.PubMedCrossRef
45.
go back to reference Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, et al. In vivo capture and label-free detection of early metastatic cells. Nat Commun. 2015;6:8094.PubMedCrossRef Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, et al. In vivo capture and label-free detection of early metastatic cells. Nat Commun. 2015;6:8094.PubMedCrossRef
46.
go back to reference Rao SS, Bushnell GG, Azarin SM, Spicer G, Aguado BA, Stoehr JR, et al. Enhanced survival with implantable scaffolds that capture metastatic breast cancer cells in vivo. Cancer Res. 2016;76(18):5209–18.PubMedPubMedCentralCrossRef Rao SS, Bushnell GG, Azarin SM, Spicer G, Aguado BA, Stoehr JR, et al. Enhanced survival with implantable scaffolds that capture metastatic breast cancer cells in vivo. Cancer Res. 2016;76(18):5209–18.PubMedPubMedCentralCrossRef
47.
go back to reference De La Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T, Lopez-Lopez R, et al. M-Trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107(9):1–10. De La Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T, Lopez-Lopez R, et al. M-Trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107(9):1–10.
48.
go back to reference Riede UN, Werner M. Tumor Complications. In: Color Atlas of Pathology: pathologic principles and assotiated diseases - sequela. 1st ed. Stuttgart: Georg Thieme Verlag; 2004. p. 352.CrossRef Riede UN, Werner M. Tumor Complications. In: Color Atlas of Pathology: pathologic principles and assotiated diseases - sequela. 1st ed. Stuttgart: Georg Thieme Verlag; 2004. p. 352.CrossRef
50.
51.
go back to reference Faraglia B, Bonsignore A, Scaldaferri F, Boninsegna A, Cittadini A, Mancuso C, et al. Caspase-3 inhibits the growth of breast cancer cells independent of protease activity. J Cell Physiol. 2005;202(2):478–82.PubMedCrossRef Faraglia B, Bonsignore A, Scaldaferri F, Boninsegna A, Cittadini A, Mancuso C, et al. Caspase-3 inhibits the growth of breast cancer cells independent of protease activity. J Cell Physiol. 2005;202(2):478–82.PubMedCrossRef
52.
go back to reference Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene. 2002;21(57):8843–51.PubMedCrossRef Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene. 2002;21(57):8843–51.PubMedCrossRef
53.
go back to reference Kruse M, Varella L, Valente S, Lebda P, Vassil A, Abraham J. Breast Cancer. In: Abraham J, Gulley JL, editors. The Bethesda Handbook of Clinical Oncology. 5th ed. Baltimore: Wolters Kluwer; 2019. p. 159–66. Kruse M, Varella L, Valente S, Lebda P, Vassil A, Abraham J. Breast Cancer. In: Abraham J, Gulley JL, editors. The Bethesda Handbook of Clinical Oncology. 5th ed. Baltimore: Wolters Kluwer; 2019. p. 159–66.
55.
go back to reference Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209 Available from: /pmc/articles/PMC4465385/. [Cited 2022 Oct 29].PubMedCrossRef Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209 Available from: /pmc/articles/PMC4465385/. [Cited 2022 Oct 29].PubMedCrossRef
56.
go back to reference Rodriguez-brenes IA, Kurtova AV, Lin C, Lee Y, Xiao J, Mims M, et al. Cellular hierarchy as a determinant of tumor sensitivity to chemotherapy Ignacio. 2018;77(9):2231–41 Rodriguez-brenes IA, Kurtova AV, Lin C, Lee Y, Xiao J, Mims M, et al. Cellular hierarchy as a determinant of tumor sensitivity to chemotherapy Ignacio. 2018;77(9):2231–41
57.
go back to reference Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42(4):20211812 Available from: /pmc/articles/PMC9069444/. [Cited 2022 Oct 29].CrossRef Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42(4):20211812 Available from: /pmc/articles/PMC9069444/. [Cited 2022 Oct 29].CrossRef
58.
go back to reference Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.PubMedCrossRef Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.PubMedCrossRef
59.
go back to reference Bullough WS. The Epithelial Tissues. In: Bullough WS, editor. The Dynamic Body Tissues. 1st ed. Lancaster: MTP Press Limited; 1983. p. 84–94.CrossRef Bullough WS. The Epithelial Tissues. In: Bullough WS, editor. The Dynamic Body Tissues. 1st ed. Lancaster: MTP Press Limited; 1983. p. 84–94.CrossRef
Metadata
Title
Eta polycaprolactone (ε-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model
Authors
Benjamin Benzon
Sandra Marijan
Matij Pervan
Vedrana Čikeš Čulić
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10813-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine